Hoth Therapeutics, Inc HOTH 深 滬
等待開盤 09-08 09:30:00 美东时间
1.33
-0.010
-0.75%
華盛通- 最 高1.3682
- 今 開1.31
- 成交量 57.85万股
- 最 低 1.31
- 昨 收 1.34
- 總市值 1756.78万
- 52周最高 3.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6506
- 委 比 -89.22%
- 總股本 1320.89万
- 歷史最高 347.00
- 量 比 0.12
- 振 幅 4.34%
- 歷史最低 0.58
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Hoth Therapeutics shares are trading higher after the company reported its antisense therapy demonstrated efficacy against KIT-driven cancers.
Hoth Therapeutics shares are trading higher after the company reported its anti...
09-02 20:22
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
Hoth Therapeutics reported strong preclinical efficacy and safety data for HT-KIT, a precision antisense therapy targeting KIT-driven cancers.
09-02 19:46
Top 5 Biotech Stocks With Strong Momentum
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
08-28 19:19
Hoth Therapeutics Renews CEO Contract Amidst Patent Filing
Hoth Therapeutics ( ($HOTH) ) has shared an announcement. On August 21, 2025, H...
08-23 04:53
Hoth Therapeutics Holds Annual Shareholder Meeting
Hoth Therapeutics ( ($HOTH) ) has provided an update. On August 5, 2025, Hoth T...
08-06 04:52
Hoth Therapeutics Announces CRADA With U.S. Department Of Veterans Affairs And FAVER To Evaluate GDNF As Metabolic Therapy Targeting Obesity And Hepatic Steatosis
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for
07-22 20:20
Hawthorn Bancshares joins Russell 3000® and Russell 2000® Indexes in FTSE Russell’s 2025 Reconstitution
Hawthorn Bancshares, Inc. (NASDAQ: HWBK) has been included in the Russell 3000 and Russell 2000 indexes, effective today. The Russell 3000 includes the largest 3,000 U.S. companies by market cap, while the Russell 2000 focuses on small-cap firms. CEO Brent M. Giles stated the inclusion reflects the company's growth and progress, enhancing visibility in the investment community.
06-30 20:48
Hoth Therapeutics Advances HT-001 for Cancer Treatment
Hoth Therapeutics ( ($HOTH) ) has provided an announcement. Hoth Therapeutics h...
06-25 04:36
Hoth Therapeutics' HT-001 Achieves 100% Response In Phase 2a Trial For EGFR Inhibitor-Related Skin Toxicities
Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.Hoth Therapeutics will host a Key Opinion Leader (KOL)
06-24 22:37
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
Developed to address EGFR inhibitor-induced skin toxicities in cancer patients NEW YORK, June 23, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceut...
06-23 20:03
